Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
6 min read
Mogamulizumab Biologics Sequence Review Report 2026: CCR4 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mogamulizumab, an antibody targeting CCR4.
Latest Hotspot
8 min read
NCT07565870 Methadone Hydrochloride Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07565870 clinical trial report covering Methadone Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07564141 Rinatabart Sesutecan Platinum-Sensitive Ovarian Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07564141 clinical trial report covering Rinatabart Sesutecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Alemtuzumab Biologics Sequence Review Report 2026: CD52 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alemtuzumab, an antibody targeting CD52.
Latest Hotspot
8 min read
NCT07567001 Zenagamtide Heart Failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07567001 clinical trial report covering Zenagamtide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07568535 Remestemcel-L-rknd Refractory Acute Graft Versus Host Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07568535 clinical trial report covering Remestemcel-L-rknd, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07571161 Donanemab-AZBT Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07571161 clinical trial report covering Donanemab-AZBT, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Inebilizumab Biologics Sequence Review Report 2026: CD19 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Inebilizumab, an antibody targeting CD19.
Latest Hotspot
8 min read
NCT07570823 SCTB-35 Diffuse large B-cell lymphoma recurrent Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07570823 clinical trial report covering SCTB-35, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07571109 Zenagamtide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07571109 clinical trial report covering Zenagamtide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Tafasitamab Biologics Sequence Review Report 2026: CD19 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tafasitamab, an antibody targeting CD19.
Latest Hotspot
8 min read
NCT07571005 Zenagamtide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07571005 clinical trial report covering Zenagamtide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.